A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors

Trial Identifier: TED17644
Sponsor: Kadmon, a Sanofi Company
Start Date: March 2023
Primary Completion Date: December 2023
Study Completion Date: December 2023
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United States, California Santa Monica, California, United States, 90404
United States, Florida Tampa, Florida, United States, 33612
United States, New York Buffalo, New York, United States, 14263
United States, Pennsylvania Philadelphia, Pennsylvania, United States, 19111
United States, Pennsylvania Pittsburgh, Pennsylvania, United States, 15232